Assessment of immunosuppressant drug carcinogenicity: Standard and alternative animal models

Human and Experimental Toxicology

Volumn 19, Issue 4, 2000, Pages 261-265

  Hastings, K L ^a,b  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^b Div Spec Pathog Immunologic D   (United States)

Author keywords

Alternative models; Carcinogenicity; Immunosuppressants

Indexed keywords

IMMUNOSUPPRESSIVE AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; BIOASSAY; CARCINOGENICITY; CONFERENCE PAPER; GENOTOXICITY; GRAFT REJECTION; LONG TERM CARE; NONHUMAN; PRIORITY JOURNAL; RISK ASSESSMENT; RODENT;

ANIMALIA; RODENTIA;

EID: 0033944662     PISSN: 09603271     EISSN: None     Source Type: Journal    
DOI: 10.1191/096032700678815837     Document Type: Conference Paper

References (49)

1. Disney APS (ed.). The Twentieth Annual Report. Australia and New Zealand Dialysis and Transplant Registry. Adelaide, Australia: Queen Elizabeth Hospital; 1997.
2. Penn I. Neoplastic complications of organ transplantation. In: Ginns LC, Cosimi AB, Morris PJ (eds.) Transplantation. Blackwell, Cambridge, 1998.
3. Penn I. Occurrence of cancers in immunosuppressed organ transplant recipients. In: Cecka JM, Terasaki PI (eds.) Clinical Transplants 1998. UCLA Tissue Typing Laboratory, Los Angeles, 1999.
4. Sheil AGR. Patterns of malignancies following renal transplantation. Transplantation Proceedings 1999; 31: 1263-1265.
5. Sheil AGR. Cancer in dialysis and transplant patients. In: Morris PJ (ed.) Kidney Transplantation. W.B. Saunders Company, Philadelphia, 1994.
6. London NJ, et al. Risk of neoplasia in renal transplant patients. Lancet 1995; 346: 403-406.
7. Penn I. The role of immunosuppression in lymphoma formation. Springer Seminars in Immunopathology 1998; 20: 343-355.
8. Diasio RB, LoBuglio AF. Immunomodulators: immunosuppressive agents and immunostimulants. In: Hardman JG, Limbird LE (eds.) Goodman and Gilman's The Pharmacological Basis of Therapeutics. McGraw-Hill, New York, 1996.
9. Ashby J, Tennant RW. Chemical structure, Salmonella mutagenicity and extent of carcinogenicity as indicators of genotoxic carcinogenesis among 222 chemicals tested in rodents by the U.S. NCI/NTP. Mutation Research 1988; 204; 17-115.
10. Cohen SM, Erturk E, Skibba JL, Bryan GT. Azathioprine induction of lymphomas and squamous cell carcinomas in rats. Cancer Research 1983; 43: 2768-2772.
11. Schreiber SL, Crabtree GR. The mechanism of action of cyclosporin A and FK506. Immunology Today 1992; 13: 136-142.
12. Walsh CT, Zydowsky LD, McKeon FD. Cyclosporin A, the cyclophilin class of peptidylprolyl isomerases, and blockade of T cell signal transduction. Journal of Biological Chemistry 1992; 267: 13115-13118.
13. Steiner JP et al. Neurotrophic actions of nonimmunosuppressive analogues of immunosuppressive drugs FK506, rapamycin and cyclosporin A. Nature Medicine 1997; 3: 421-428.
14. New Drug Application 50-715; approved Nov. 14, 1983.
15. New Drug Application 50-708; approved April 8, 1994.
16. Voisin EM, Ruthsatz M, Collins JM, Hoyle PC. Extrapolation of animal toxicity to humans: interspecies comparisons in drug development. Regulatory Toxicology and Pharmacology 1990; 12: 107-116.
17. Ryffel B et al. Toxicological evaluation of cyclosporin A. Archives of Toxicology 1983; 53: 107-141.
18. Tamura K. FK506: mechanism of immunosuppression and adverse effects. Journal of Toxicological Science 1995; 20: 477-479.
19. Ryffel B. The carcinogenicity of ciclosporin. Toxicology 1992; 73: 1-22.
20. Griesmacher A, Weigel G, Seebacher G, Muller MM. IMP-dehydrogenase inhibition in human lymphocytes and lymphoblasts by mvcophenolic acid and mycophenolic acid glucuronide. Clinical Chemistry 1997; 43: 2312-2317.
21. Becker BN. Mycophenolate mofetil. Transplantation Proceedings 1999; 31: 2777-2778.
22. New Drug Application 20-513; approved May 3, 1995.
23. IARC. Monographs on the Evaluation of Carcinogenic Risks to Humans. Vol. 50. Pharmaceutical Drugs. International Agency for Research on Cancer, Lyons, France, 1990.
24. Olshan AF, Mattison DR, Zwanenburg TSB. Cyclosporine A: review of genotoxicity and potential for adverse human reproductive and developmental effects. Mutation Research 1994; 317: 163-173.
25. Bieber CP, Pennock JL, Reitz BA. Lymphoma in cyclosporin A - treated nonhuman primate allograft recipients. In: Rosenberg S, Kaplan H (eds.) Malignant Lymphomas. Academic Press, New York, 1982.
26. Rosenkranz HS, Klopman G. A structural analysis of the genotoxic and carcinogenic potentials of cyclosporin A. Mutagenesis 1992; 7: 115-118.
27. Penn I. Cancers following cyclosporine therapy. Transplantation 1987; 43: 32-35.
28. Vial T. Cancers in immunocompromised hosts. Journal de Toxicologie clinique et Experimentale 1992; 12: 385-395.
29. Yokoyama I et al. Accelerated growth rates of recurrent hepatocellular carcinoma after liver transplantation. Cancer 1991; 68: 2095-2100.
30. Hattori A et al. Diversity of the promoting action of cyclosporine on the induction of murine lymphoid tumors. Carcinogenesis 1988; 9: 1091-1094.
31. Perera MIR, Kunz HVV, Gill TJ, Shinozuka H. Enhancement of induction of intestinal adenocarcinomas by cyclosporine in rats given a single dose of N-methyl N-nitrosourea. Transplantation 1986; 42: 297-302.
32. Reddi AS, Jyothirmayi GN, Halka K, Khan MY. Potentiation of renal tumorigenicity by cyclosporine A in streptozotocin diabetic rats. Cancer Letters 1991; 56: 109-115.
33. Shinozuka H, Hattori A, Gill TJ, Kunz HW. Experimental models of malignancies after cyclosporine therapy. Transplantation Proceedings 1988; 20: 893-899.
34. Kelly GE, Meikle W, Sheil AGR. Effects of immunosuppressive therapy on the induction of skin tumors by ultraviolet irradiation in hairless mice. Transplantation 1987; 44: 429-434.
35. Nelson EW, Eichwald EJ, Shelby J. Increased ultraviolet radiation-induced skin cancers in cyclosporine-treated mice. Transplantation Proceedings 1987; 19: 526-527.
36. Luster MI et al. Risk assessment in immunotoxicology. II. Relationships between immune and host resistance tests. Fundamental and Applied Toxicology 1993; 21: 71-82.
37. Freise CE et al. Effect of systemic cyclosporine on tumor recurrence after liver transplantation in a model of hepatocellular carcinoma. Transplantation 1999; 67: 510-513.
38. Masuhara M et al. Cyclosporine stimulates hepatocyte proliferation and accelerates development of hepatocellular carcinomas in rats. Carcinogenesis 1993; 14: 1579-1584.
39. Shimizu T et al. Effects of cyclosporin A on progressive and regressive tumors induced by two cancer lines derived from a single colon carcinoma chemically induced in the rat. Immunobiology 1989; 178: 401-415.
40. Van der Elst J et al. Quantitative study of liver metastases from colon cancer in rats after treatment with cyclosporine A. Journal of the National Cancer Institute 1986; 77: 227-232.
41. Van de Vrie W, Marquet RL, Eggermont AMM. Cyclosporin A enhances locoregional metastasis of the CC531 rat colon tumour. Journal of Cancer Research and Clinical Oncology 1997; 123: 21-24.
42. Tennant RW, French JE, Spalding JW. Identifying chemical carcinogens and assessing potential risk in short-term bioassays using transgenic mouse models. Environmental Health Perspectives 1995; 103: 942-950.
43. Eastin WC, Haseman JK, Mahler JF, Bucher JR. The National Toxicology Program evaluation of genetically altered mice as predictive models for identifying carcinogens. Toxicologic Pathology 1998; 26: 461-473.
44. Mahler JF et al. Spontaneous and chemically induced proliferative lesions in Tg.AC transgenic and p53-heterozygous mice. Toxicologic Pathology 1998; 26: 501-511.
45. Hojo M et al. Cyclosporine induces cancer progression by a cell-autonomous mechanism. Nature 1999; 397: 530-534.
46. Khanna AK, Hosenpud JD. Cyclosporine induces the expression of the cyclin inhibitor p21. Transplantation 1999; 67: 1262-1268.
47. Shehata M et al. Cyclosporine enhances the expression of TGF-3 in the juxtaglomerular cells of the rat kidney. Kidney International 1995; 48: 1487-1496.
48. Wolf G, Thaiss F, Stahl RAK. Cyclosporine stimulates expression of transforming growth factor-3 in renal cells. Transplantation 1995; 60: 237-241.
49. Nabel GJ. A transformed view of cyclosporine. Nature 1999; 397: 471-472.